No Data
No Data
Zymeworks (NASDAQ:ZYME) Investors Are Sitting on a Loss of 75% If They Invested Three Years Ago
Subdued Growth No Barrier To Zymeworks Inc.'s (NASDAQ:ZYME) Price
It's not a stretch to say that Zymeworks Inc.'s (NASDAQ:ZYME) price-to-sales (or "P/S") ratio of 13.6x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in the United
Form 144 | Zymeworks(ZYME.US) Insider Proposes to Sell 774.06K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 11, $Zymeworks(ZYME.US)$ Insider Christopher Astle intends to sell 86,294 shares of its common stock on Jun 11, with a total market value of approximately $774.06K. Sour
Sector Update: Health Care Stocks Decline Premarket Monday
Health care stocks were declining premarket Monday as the iShares Biotechnology ETF (IBB) was 0.5% lower and the Health Care Select Sector SPDR Fund (XLV) was down 0.3% recently. Skye Bioscience (SKYE
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy
Zymeworks (ZYME) said Monday that China's health regulator has accepted the Biologics License Application for its second-line experimental treatment of HER2-positive biliary tract cancer, zanidatamab.
Zymeworks' BLA For Zanidatamab For HER2-positive BTC Accepted By CDE In China